



PhRMA Efforts in Japan to Combat COVID-19

Chris Hourigan | Chair, Japan Based Executive Committee

PhRMA
RESEARCH • PROGRESS • HOPE

Working in Partnership with Japan against COVID-19 to Realize a Prosperous “Post-Corona” Japan

Our efforts will help control infections, support frontline workers, restore people’s daily lives and restart the Japanese economy



**Treatments and
vaccines**



**Donations and in-kind
support**



**Stable supply and
manufacturing**

Helping Those Affected by COVID-19

TREATMENTS AND VACCINES

- Donated a portion of the 1.5 million vials manufactured of the only drug approved for COVID-19
- Collaborated with the Ministry of Health, Labor and Welfare and provided multiple drug compounds to the National Institute of Infectious Diseases

DONATIONS AND IN-KIND SUPPORT

- Tens of millions of yen in financial support to medical/research institutions, NGOs and patients
- Hundreds of thousands of masks, PPE and other medical supplies to health care workers
- Launched matching employee gift and new scholarship programs

STABLE SUPPLY/MANUFACTURING

- Constantly monitoring supply chain conditions to ensure stable supply of medicines in Japan
- Working closely with authorities to prevent and mitigate any potential shortages
- Ramping up output of existing medicines with demonstrated benefit
- Investing in infrastructure to accelerate production of new products

The Biopharmaceutical Industry Remains Committed to Working with Japan

Our fight against COVID-19 will continue until prevention and treatment become available.

To develop new treatments and vaccines and provide them to Japanese citizens at the earliest possible timing

To help address COVID-19 challenges and realize a prosperous “post-corona future”

